Blood and Immune System Convergence in ME/CFS

1 Seifert et al. 2026 — Extracellular Vesicle Signatures as Biomarkers

Full Citation:: Seifert M, Sch{"a}fers J, Douglas FF, et al. Extracellular Vesicle Protein and MiRNA Signatures as Biomarkers for Post-Infectious ME/CFS Patients. Int J Mol Sci. 2026;27(5). DOI:: 10.3390/ijms27052314 PMID:: 41828537 Study Design:: Case-control; plasma EV isolation by size-exclusion chromatography; proteomics + small RNA sequencing Sample Size:: n<=10/cohort (proteomics); n=12 post-COVID ME/CFS vs n=15 HC (miRNA); all female Key Findings::

- Altered EV cargo proteins: hemoglobin subunit alpha, IGFBP acid labile subunit
- hsa-let-7b-5p downregulated in post-COVID ME/CFS EVs
- Reduced hsa-let-7b-5p correlated with impaired physical functioning, fatigue, pain, immune activation

Conclusion:: EV cargo and miRNA signatures are promising biomarker candidates for diagnosis and stratification Limitations:: Very small n; female-only; no replication; discovery phase Certainty Assessment::

- *Quality:* Low (very small n, mid-tier journal, no replication)
- *Score:* 0.30

2 Bragee et al. 2026 — CSF Proteomic Signatures in ME/CFS

Full Citation:: Bragee B, Li P, Meadows D, et al. Proteomic signatures in cerebrospinal fluid and their clinical associations in patients with ME/CFS. Sci Rep. 2026. DOI:: 10.1038/s41598-026-46965-1 PMID:: 41932997 Study Design:: Cross-sectional CSF proteomics with clinical factor analysis Sample Size:: n=31 ME/CFS patients (no control group) Key Findings::

- 902 CSF proteins quantified
- Neutrophil degranulation, platelet activation enriched in POTS+ patients
- Complement cascade, coagulation, IGFBP-mediated IGF transport enriched in severe cases
- Four severity-associated protein ratios identified

Conclusion:: CSF proteomics reveals biological processes associated with clinical heterogeneity; POTS+ patients show distinct inflammatory/coagulation signatures Limitations:: No control group; n=31; single-center; ratio-based analysis only Certainty Assessment::

- *Quality:* Medium-low (no controls, small n, mid-tier journal)
- *Score:* 0.35

3 Yu et al. 2026 — White Matter Neuroinflammation via Diffusion MRI

Full Citation:: Yu Q, Kothe K, Kwiatek RA, et al. Evidence of White Matter Neuroinflammation in ME/CFS: A Diffusion-Based Neuroinflammation Imaging Study. Hum Brain Mapp. 2026;47(4):e70505. DOI:: 10.1002/hbm.70505 PMID:: 41834684 Study Design:: Case-control advanced diffusion MRI with neuroinflammation imaging (NII) model Sample Size:: n=67 ME/CFS vs 67 matched HC (54F/13M per group) Key Findings::

- Widespread white matter abnormalities: lower NII-HR (cerebral edema), lower NII-RF (cellular infiltration), higher NII-FF (axonal reorganization)
- Conventional DTI showed minimal differences --- NII far more sensitive
- NII metrics correlated with mental health, disability, disease severity

Conclusion:: First in vivo evidence of white matter neuroinflammation in ME/CFS using advanced NII model; NII metrics substantially more sensitive than conventional DTI Limitations:: Cross-sectional; single-center; NII model needs further validation Certainty Assessment::

- *Quality:* Medium-high (n=67/group, rigorous matching, advanced methodology, reputable journal)
- *Replication:* No direct replication yet
- *Score:* 0.60

4 Shahbaz et al. 2025 — Integrated Immune, Hormonal, and Transcriptomic Sex-Specific Dysregulation in LC-ME/CFS

Full Citation:: Shahbaz S, Osman M, Syed H, Mason A, Rosychuk RJ, Cohen Tervaert JW, Elahi S. Integrated immune, hormonal, and transcriptomic profiling reveals sex-specific dysregulation in long COVID patients with ME/CFS. Cell Reports Medicine. 2025;6(11):102449. (Shahbaz et al. 2025) DOI:: 10.1016/j.xcrm.2025.102449 PMID:: 41205594 Study Design:: Integrated immune, hormonal, and transcriptomic profiling of Long COVID patients with ME/CFS Key Findings::

- Sex-specific immune dysregulation: females show decreased lymphocytes with increased neutrophils and monocytes (myelopoiesis shift), elevated pro-inflammatory cytokines, and upregulated type 2 interferon signaling (IP-10, IFN-$\gamma$)
- Males show fewer inflammatory alterations, more balanced profiles, elevated anti-inflammatory IL-10, and IL-1 signaling dominance rather than interferon predominance
- Sex differences in immune profiles likely reflect hormonal influences on immune cell development, activation, and cytokine production

Conclusion:: Female-predominant sex-specific immune dysregulation in Long COVID with ME/CFS, consistent with the 3–4:1 female predominance of the disease and with estrogen-modulated immune responses Limitations:: Long COVID ME/CFS cohort; not idiopathic ME/CFS; sex-specific hormonal mechanisms inferred, not directly measured Certainty Assessment::

- *Quality:* Medium (integrated multi-omics, reputable journal, but Long-COVID cohort; hormonal mechanism inferred)
- *Score:* 0.50

Note:: Previously mis-attributed in the bibliography to “Heng, Ruiwen Benjamin” with an invalid DOI (10.1016/j.xcrm.2025.102221); corrected to the true first author (Shahbaz S) and valid DOI (10.1016/j.xcrm.2025.102449) per PubMed PMID 41205594.

5 Shahbaz et al. 2026 — Single-Cell Immune Remodeling in LC-ME/CFS

Full Citation:: Shahbaz S, Bozorgmehr N, Rahmati A, et al. Single-cell analysis reveals immune remodeling of monocytes, NK cells, T cell exhaustion, and Galectin-9-associated depletion of gamma delta and MAIT cells in Long COVID with ME/CFS. Front Immunol. 2026;17:1745933. DOI:: 10.3389/fimmu.2026.1745933 PMID:: 41822518 Study Design:: Single-cell RNA-seq of PBMCs from LC-ME/CFS patients Sample Size:: Female LC-ME/CFS vs recovered (12 months post-COVID); compared with public idiopathic ME/CFS datasets Key Findings::

- Reduced naive CD4+/CD8+, Tregs, MAIT cells, gamma-delta T cells; expanded effector T cells
- NK cells reduced with altered activation; monocytes: reduced phagocytosis, increased pro-inflammatory genes
- Galectin-9--TIM-3 identified as driver of gamma-delta and MAIT cell depletion
- Idiopathic ME/CFS: less pronounced changes, no MAIT/NK reduction, no T cell exhaustion

Conclusion:: Extensive peripheral immune remodeling in LC-ME/CFS distinct from idiopathic ME/CFS; Galectin-9–TIM-3 axis is a novel mechanistic target Limitations:: Female-only; cross-dataset comparison introduces batch effects; no replication Certainty Assessment::

- *Quality:* Medium (scRNA-seq powerful, novel mechanism, reputable OA journal, but small n, batch effects)
- *Score:* 0.50

6 Maya et al. 2026 — Complement Genetics and Inflammatory Subgroup

Full Citation:: Maya J, Unger ER, Lin JS, Rajeevan MS. Genetic Insights into Circulating Complement Proteins in ME/CFS: A Potential Inflammatory Subgroup. Int J Mol Sci. 2026;27(3). DOI:: 10.3390/ijms27031574 PMID:: 41683992 Study Design:: pQTL analysis of complement proteins; linear/logistic regression; UK Biobank validation Sample Size:: 50 ME/CFS vs 121 non-fatigued; UK Biobank replication Key Findings::

- Alternative complement pathway dysregulation in ME/CFS subset (high C3/low Bb profile)
- 6 pQTLs also associated with fatigue phenotypes in UK Biobank (4 complement-related)
- Identifies inflammatory complement subgroup

Conclusion:: Genetic basis for complement dysregulation in a ME/CFS inflammatory subgroup; many roads may lead to complement activation Limitations:: Small discovery cohort; general population controls; pQTL is indirect measure Certainty Assessment::

- *Quality:* Medium (novel genetic approach, UK Biobank partial validation, CDC authorship, but small discovery n)
- *Score:* 0.50

7 Nguyen et al. 2017 — First TRPM3 Impairment in ME/CFS NK Cells

Full Citation:: Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187(2):284–293. DOI:: 10.1111/cei.12882 PMID:: 27727448 Study Design:: Case-control; flow cytometry, calcium flux assays in NK cell subtypes Sample Size:: n=15 CFS/ME patients, n=25 healthy controls Key Findings::

- Unstimulated CD56bright NK cells: significantly reduced TRPM3 surface expression in CFS/ME vs controls
- PregS-stimulated CD56bright NK cells: elevated Ca^2+^ flux in CFS/ME patients vs controls
- Thapsigargin-stimulated CD56dim NK cells: elevated cytotoxicity in CFS/ME
- Differential TRPM3 expression patterns between NK cell subtypes

Conclusion:: First study linking TRPM3 dysfunction to impaired calcium mobilization in ME/CFS NK cells; identifies TRPM3 as pathomechanistic candidate Limitations:: Small n; unequal group sizes; cross-sectional; single center (Griffith University) Certainty Assessment::

- *Quality:* Medium (peer-reviewed clinically relevant journal, but small n, single center)
- *Replication:* Replicated by multiple subsequent studies from same group and Sasso et al. 2026
- *Score:* 0.55

8 Cabanas et al. 2019a — Validation of TRPM3 Dysfunction (Patch-Clamp)

Full Citation:: Cabanas H, Muraki K, Balinas C, Eaton-Fitch N, Staines D, Marshall-Gradisnik S. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Mol Med. 2019;25(1):14. DOI:: 10.1186/s10020-019-0083-4 PMID:: 31014226 Study Design:: Case-control; whole-cell patch-clamp electrophysiology Sample Size:: n=12 CFS/ME, n=12 age/sex-matched healthy controls Key Findings::

- Significantly reduced amplitude of TRPM3 currents in CFS/ME NK cells
- Confirmed using multiple pharmacological probes: PregS (agonist), nifedipine, ononetin (antagonist)
- Establishes TRPM3 dysfunction as potential diagnostic biomarker

Conclusion:: Electrophysiological validation of TRPM3 loss of function in ME/CFS NK cells; supports ion channelopathy model Limitations:: Small n; single center; NK cells only; patch-clamp is labor-intensive limiting scale Certainty Assessment::

- *Quality:* Medium (rigorous patch-clamp methodology, peer-reviewed, but small n)
- *Replication:* Validated by Sasso et al. 2026 multi-site study
- *Score:* 0.55

9 Cabanas et al. 2019b — Naltrexone Restores TRPM3 Function In Vitro

Full Citation:: Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Front Immunol. 2019;10:2545. DOI:: 10.3389/fimmu.2019.02545 PMID:: 31736966 Study Design:: Case-control; patch-clamp; in vitro naltrexone incubation Sample Size:: n=8 ME/CFS, n=8 age/sex-matched healthy controls Key Findings::

- Impaired TRPM3 function confirmed in ME/CFS NK cells
- 24h naltrexone (NTX) incubation fully restores TRPM3 channel activity in IL-2-stimulated NK cells
- NTX mechanism: opioid receptor antagonism removes inhibitory block on TRPM3
- First pharmacological restoration of TRPM3 function in ME/CFS

Conclusion:: Proof-of-concept that TRPM3 dysfunction is pharmacologically reversible; supports LDN as therapeutic candidate Limitations:: Very small n (8/group); in vitro only; mechanism inferred; single center Certainty Assessment::

- *Quality:* Medium-low (small n, in vitro, but rigorous electrophysiology, high-impact open-access journal)
- *Replication:* Confirmed by Eaton-Fitch et al. 2022 (n=10/group) and Cabanas et al. 2025
- *Score:* 0.50

10 Eaton-Fitch et al. 2021 — TRPM3/PIP2 Co-Localization and NK Degranulation

Full Citation:: Eaton-Fitch N, Cabanas H, du Preez S, Staines D, Marshall-Gradisnik S. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localization with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. 2021;19:306. DOI:: 10.1186/s12967-021-02974-4 PMID:: 34266470 Study Design:: Case-control; confocal microscopy, flow cytometry, cytotoxicity assay Sample Size:: n=15 ME/CFS, n=15 age/sex-matched healthy controls Key Findings::

- TRPM3/PIP2 co-localization significantly reduced in ME/CFS NK cells vs controls
- PIP2-dependent Ca^2+^ entry required for granule polarization, perforin pore formation, granzyme-dependent apoptosis
- IL-2 stimulation significantly enhances NK cytotoxicity in both groups; partially compensates for TRPM3 dysfunction
- Ononetin treatment enhanced TRPM3/PIP2 co-localization in patient cells

Conclusion:: TRPM3–PIP2 interaction is mechanistically upstream of NK cell degranulation; its disruption explains reduced cytotoxic killing in ME/CFS Limitations:: n=15/group; single center; indirect degranulation readout; confocal co-localization is semi-quantitative Certainty Assessment::

- *Quality:* Medium (mechanistically informative, peer-reviewed, adequate n for exploratory study)
- *Score:* 0.50

11 Eaton-Fitch et al. 2022 — TRPM3 Calcium Influx and Naltrexone Restoration (Expanded)

Full Citation:: Eaton-Fitch N, du Preez S, Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. 2022;20(1):94. DOI:: 10.1186/s12967-022-03297-8 PMID:: 35172836 Study Design:: Case-control; calcium flux assay (live cell imaging), in vitro naltrexone Sample Size:: n=10 ME/CFS, n=10 age/sex-matched healthy controls Key Findings::

- Ca^2+^ response amplitude and T1/2 significantly reduced at baseline in ME/CFS NK cells vs HC (p < 0.0001)
- Overnight naltrexone treatment fully restores TRPM3-dependent Ca^2+^ influx to HC levels
- Both response timing and amplitude normalized post-NTX
- Validates and extends Cabanas et al. 2019b with improved sample size

Conclusion:: Strengthened evidence for TRPM3 dysfunction as core ME/CFS abnormality; naltrexone pharmacological rescue confirmed in larger cohort Limitations:: Small n (10/group); in vitro pharmacology; single center; no clinical correlation Certainty Assessment::

- *Quality:* Medium (improved n vs prior study, rigorous methodology, peer-reviewed)
- *Replication:* Builds directly on Cabanas 2019b; further confirmed by Cabanas 2025
- *Score:* 0.55

12 du Preez et al. 2023 — TRPM7 Calcium Dysregulation in ME/CFS NK Cells

Full Citation:: du Preez S, Eaton-Fitch N, Smith PK, Marshall-Gradisnik S. Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Biomolecules. 2023;13(7):1039. DOI:: 10.3390/biom13071039 PMID:: 37509075 Study Design:: Case-control; calcium flux assay (TRPM7 agonist/antagonist pharmacology) Sample Size:: n=9 ME/CFS, n=9 age/sex-matched healthy controls Key Findings::

- TRPM7-dependent Ca^2+^ influx slope significantly reduced in ME/CFS following TRPM7 activation
- Response parameters during TRPM7 desensitization also significantly differ between groups
- Suggests broader TRP channelopathy beyond TRPM3 alone
- Authors propose TRPM7 dysfunction may reflect downstream consequence of impaired Ca2+ homeostasis

Conclusion:: ME/CFS involves multi-channel TRP channelopathy; TRPM7 adds to TRPM3 as dysregulated calcium channel in NK cells Limitations:: Very small n (9/group); single center; unclear if primary or secondary TRPM7 dysfunction; single cell type Certainty Assessment::

- *Quality:* Low-medium (very small n, exploratory, but peer-reviewed open access, rigorous methodology)
- *Replication:* Not yet independently replicated
- *Score:* 0.45

13 Vijayan et al. 2015 — Thalamic Alpha-Delta Sleep Mechanism

Full Citation:: Vijayan S, Klerman EB, Adler GK, Kopell NJ. Thalamic mechanisms underlying alpha-delta sleep with implications for fibromyalgia. J Neurophysiol. 2015;114(3):1923–1930. DOI:: 10.1152/jn.00280.2015 PMID:: 26245315 Study Design:: Computational biophysical modeling of thalamocortical circuits Sample Size:: Mathematical model (no human/animal subjects) Key Findings::

- Alterations in GABAB currents, Ih (hyperpolarization-activated), and K+ leak currents transform normal delta oscillations into pathological alpha-delta pattern
- CaV3 T-type channels prevalent in thalamus; model implicates ionic substrate of sleep oscillation generation
- Alpha-delta sleep prevalent in fibromyalgia; artificially induced alpha intrusion causes fibromyalgia-like pain in healthy subjects
- Predicts: drugs reducing Ih conductances and/or increasing K+ conductances may restore delta sleep

Conclusion:: Provides mechanistic thalamic circuit model for non-restorative sleep; alpha-delta pattern explained by specific ionic current imbalances involving T-type Ca²⁺ channel substrates Limitations:: Theoretical model only; no direct ME/CFS data; applicable by analogy via fibromyalgia/non-restorative sleep overlap Certainty Assessment::

- *Quality:* Medium (rigorous computational approach, top physiology journal, but model-only, indirect ME/CFS relevance)
- *Score:* 0.50

14 Crunelli et al. 2006 — Thalamic T-Type Ca2+ Channels and NREM Sleep

Full Citation:: Crunelli V, Cope DW, Hughes SW. Thalamic T-type Ca²⁺ channels and NREM sleep. Cell Calcium. 2006;40(2):175–190. DOI:: 10.1016/j.ceca.2006.04.022 PMID:: 16777223 Study Design:: Review and primary electrophysiology; CaV3.1 knockout mouse studies Sample Size:: Animal model (CaV3.1 KO mice) and review of literature Key Findings::

- T-type Ca^2+^ channels generate low-threshold potentials underlying sleep spindles and delta waves
- CaV3.1 knockout mice: significantly reduced total NREM sleep duration
- CaV3.1 established as most crucial voltage-dependent conductance for thalamic sleep activity
- Persistent opening of small fraction of T channels drives slow-oscillation depolarization phase

Conclusion:: Foundational mechanistic basis for how disruption of thalamic T-type Ca²⁺ channels impairs delta/NREM sleep architecture; relevant to non-restorative sleep in fibromyalgia and ME/CFS Limitations:: Primarily animal data; extrapolation to human ME/CFS requires caution; 2006 review may miss recent refinements Certainty Assessment::

- *Quality:* High for basic science (KO model, rigorous electrophysiology, peer-reviewed); indirect ME/CFS relevance
- *Score:* 0.65

15 Germain et al. 2025 — Plasma Proteome Dynamics Post-Exertion

Full Citation:: Germain A, Glass KA, Eckert MA, et al. Temporal Dynamics of the Plasma Proteomic Landscape Reveals Maladaptation in ME/CFS Following Exertion. Mol Cell Proteomics. 2025;24(12):101467. DOI:: 10.1016/j.mcpro.2025.101467 PMID:: 41237904 Study Design:: Longitudinal plasma proteomics (SomaScan 7K) before/after maximal exercise; 2 CPET tests Sample Size:: n=79 ME/CFS vs n=53 sedentary controls (132 total) Key Findings::

- Most pronounced proteomic alterations during recovery phase (PEM onset)
- Persistent dysregulation of immune, metabolic, neuromuscular pathways
- T/B cell signaling suppressed; IL-17 and cell-cell communication downregulated
- Glycolysis/gluconeogenesis upregulated --- mitochondrial stress
- Sex-stratified analyses: distinct molecular responses females vs males
- Symptom severity correlated with immune protein changes

Conclusion:: Dynamic proteomics captures PEM maladaptation at molecular level; sedentary controls distinguish disease from deconditioning Limitations:: Single-center; 24h recovery may miss later PEM dynamics Certainty Assessment::

- *Quality:* Medium-high (n=132 largest proteomics study, longitudinal, sedentary controls, top-tier journal)
- *Replication:* No independent replication; builds on prior metabolomics work
- *Score:* 0.65

16 Germain et al. 2017 — ME/CFS Plasma Metabolomics: Taurine Pathway Disturbance

Full Citation:: Germain A, Ruppert D, Levine SM, Hanson MR. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. 2017;13(2):371–379. DOI:: 10.1039/c6mb00600k PMID:: 28059425 Study Design:: Untargeted plasma metabolomics; LC-MS; cross-sectional Sample Size:: n=17 ME/CFS vs n=15 matched controls Key Findings::

- 74 differentially accumulated metabolites identified in ME/CFS plasma
- Top disturbed pathways: taurine metabolism, glycerophospholipid metabolism, bile acid metabolism
- Energy-related compounds and glucose regulation significantly affected
- Taurine pathway disruption among the highest-ranked metabolic signatures in ME/CFS
- Consistent with systemic metabolic dysfunction hypothesis (hypometabolism)

Conclusion:: ME/CFS is characterized by a disrupted taurine metabolic signature alongside lipid and energy pathway dysregulation; provides direct biochemical evidence of taurine relevance in ME/CFS patients Limitations:: Small discovery cohort (n=17); cross-sectional; no replication cohort in this paper; does not measure free plasma taurine levels directly Certainty Assessment::

- *Quality:* Medium (peer-reviewed, respected group, but n=17; requires replication)
- *Replication:* Taurine metabolomics disturbance partially supported by Glass 2023 urine metabolomics
- *Score:* 0.55

17 Glass et al. 2023 — Urine Metabolomics Post-Exertion: Impaired Taurine Recovery

Full Citation:: Glass KA, Germain A, Huang YV, Hanson MR. Urine Metabolomics Exposes Anomalous Recovery after Maximal Exertion in Female ME/CFS Patients. Int J Mol Sci. 2023;24(4):3685. DOI:: 10.3390/ijms24043685 PMID:: 36835097 Study Design:: Urine metabolomics pre/post maximal cardiopulmonary exercise test (CPET); longitudinal Sample Size:: n=10 female ME/CFS vs n=8 healthy controls Key Findings::

- ME/CFS patients showed virtually no metabolomic recovery response after maximal exertion
- Controls demonstrated significant post-exercise metabolic adaptations; ME/CFS did not
- Significant differences in lipid and amino acid pathways including taurine metabolism during PEM
- Results suggest failure of normal physiological adaptation to physical stress
- Urine taurine pathway: disrupted in ME/CFS recovery window (PEM period)

Conclusion:: Metabolomic evidence that PEM in ME/CFS involves impaired amino acid and lipid pathway recovery, including taurine; supports the hypothesis of defective metabolic adaptation post-exertion Limitations:: Very small n (10 ME/CFS); female-only cohort; single time-point recovery measurement; pilot study Certainty Assessment::

- *Quality:* Low-medium (very small n; pilot; female-only; requires replication in larger mixed cohorts)
- *Replication:* None to date for urine taurine specifically
- *Score:* 0.45

18 Singh et al. 2023 — Taurine Deficiency as a Driver of Aging

Full Citation:: Singh P, Gollapalli K, Mangiola S, et al. Taurine deficiency as a driver of aging. Science. 2023;380(6649):eabn9257. DOI:: 10.1126/science.abn9257 PMID:: 37289866 Study Design:: Multi-species observational (mice, primates, humans) + supplementation RCT (rodents/primates); lifespan and healthspan endpoints Sample Size:: Large multi-arm; human cross-sectional cohort (n not specified in abstract); rodent lifespan study (hundreds of mice) Key Findings::

- Taurine concentrations decline progressively with age across mice, monkeys, and humans
- Taurine supplementation extended average lifespan in mice by ~10--12%; improved healthspan in primates
- Mechanisms: reduced cellular senescence, telomerase protection, suppressed mitochondrial dysfunction, decreased DNA damage, attenuated inflammaging
- Exercise transiently elevates taurine levels in humans
- Human clinical trials recommended

Conclusion:: Landmark multi-species evidence that taurine deficiency is a systemic driver of aging via mitochondrial and senescence pathways; directly relevant to ME/CFS hypotheses linking taurine depletion to chronic cellular dysfunction Limitations:: Human data cross-sectional only; causality not established in humans; contradicted by Marcangeli 2025 null result; supplementation trial in humans not yet completed Certainty Assessment::

- *Quality:* High for animal data; medium for human inference (Science, large multi-species, rigorous)
- *Replication:* Human component not replicated; Marcangeli 2025 contradicts human aging hypothesis
- *Score:* 0.65

19 Marcangeli et al. 2025 — NULL RESULT: No Taurine–Aging Link in Humans

Full Citation:: Marcangeli V, Cefis M, Hammad R, et al. Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans. Aging Cell. 2025;24(10):e70191. DOI:: 10.1111/acel.70191 PMID:: 41061678 Study Design:: Cross-sectional observational; serum taurine vs physiological and mitochondrial measures Sample Size:: n=137 men aged 20–93 (sedentary and physically active) Key Findings::

- No association between circulating taurine levels and age in humans
- No correlation with muscle mass, strength, power, or validated functional performance tests
- No link to insulin sensitivity, inflammatory markers, or mitochondrial respiration
- Mitochondrial calcium handling capacity also uncorrelated with taurine levels
- Directly contradicts Singh et al.\ 2023 hypothesis for the human aging context

Conclusion:: In humans, circulating taurine is not a biomarker of aging, physical function, or mitochondrial health; species-specific effects likely explain discrepancy with rodent/primate data; this limits extrapolation of animal taurine-depletion models to human ME/CFS Limitations:: Men only; cross-sectional; measures circulating (serum) not intracellular taurine; tissue-level depletion may not be reflected in serum Certainty Assessment::

- *Quality:* Medium-high (n=137, peer-reviewed Aging Cell, specific mechanistic tests)
- *Replication:* Single null study; does not rule out tissue-level taurine depletion
- *Score:* 0.60

20 Rossi-Smith et al. 2025 — Taurine Efflux Impairs Na/K-ATPase, Drives NLRP3

Full Citation:: Rossi-Smith P, Kim J, Skirlo K, et al. Taurine transport is a critical modulator of ionic fluxes during NLRP3 inflammasome activation. Cell Reports. 2025;44(10):116317. DOI:: 10.1016/j.celrep.2025.116317 PMID:: 40974575 Study Design:: Mechanistic cell biology + tuberculosis patient clinical cohort (immune reconstitution inflammatory syndrome) Sample Size:: In vitro (macrophage cultures) + patient cohort (n not specified) Key Findings::

- Upon inflammasome stimulation, taurine rapidly exits cells via volume-regulated anion channel (VRAC)
- Intracellular taurine depletion impairs Na/K-ATPase activity --- the primary ionic dysregulation consequence
- Disrupted Na/K-ATPase drives ionic imbalance that activates NLRP3 inflammasome and IL-1beta release
- Blocking VRAC or supplementing taurine restores Na/K-ATPase function and suppresses IL-1beta
- Taurine metabolism correlated with TB-associated immune reconstitution inflammatory syndrome in clinical cohort

Conclusion:: Taurine depletion is mechanistically upstream of Na/K-ATPase failure; this is the most direct mechanistic link to the AIMM cascade (NHE1 Na+ import → Na/K-ATPase exhaustion → NCX reversal → Ca2+ overload); taurine supplementation is a plausible intervention at the Na/K-ATPase node Limitations:: Primary data from macrophages, not muscle cells or neurons; extrapolation to AIMM tissue context requires validation; clinical cohort is TB/IRIS, not ME/CFS Certainty Assessment::

- *Quality:* Medium-high (Cell Reports, mechanistic rigor, clinical correlation)
- *Replication:* Novel 2025 finding; not independently replicated
- *Score:* 0.60

21 Suleiman 1994 — Taurine, Na/K-ATPase, and Cardiac Calcium Paradox

Full Citation:: Suleiman MS. New concepts in the cardioprotective action of magnesium and taurine during the calcium paradox and ischaemia of the heart. Magnesium Research. 1994;7(3–4):295–312. PMID:: 7786694 Study Design:: Review; synthesizes animal model and mechanistic data Sample Size:: Review (no primary data) Key Findings::

- Intracellular Na+ accumulation during ischemia drives Ca2+ overload via NCX reversal (classical mechanism)
- Taurine protects cardiac cells by promoting Na+ efflux via the taurine/Na+ symport, reducing intracellular Na+
- By reducing intracellular Na+, taurine indirectly prevents NCX reversal and subsequent Ca2+ overload
- Both taurine and Mg2+ act through preservation of Na/K-ATPase activity
- Species differences documented in protective efficacy

Conclusion:: Establishes the classic conceptual framework directly relevant to AIMM: taurine acts upstream of NCX to reduce the Na+ load that drives reverse-mode NCX and Ca2+ overload; foundational for AIMM-taurine integration hypothesis Limitations:: 1994 review; predates modern ion channel molecular tools; primarily cardiac ischemia context; no ME/CFS data Certainty Assessment::

- *Quality:* Low-medium (old review, conceptual framework, no modern molecular validation cited)
- *Replication:* Mechanism broadly accepted in cardiac physiology literature
- *Score:* 0.45

22 Prentice et al. 2015 — Taurine Neuroprotection via Calcium Buffering and Mitochondrial Stabilization

Full Citation:: Prentice H, Modi JP, Wu JY. Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases. Oxid Med Cell Longev. 2015;2015:964518. DOI:: 10.1155/2015/964518 PMID:: 26576229 Study Design:: Narrative review; synthesizes cell biology, animal model, and clinical data Sample Size:: Review (no primary data) Key Findings::

- Taurine prevents pathological Ca2+ accumulation in neurons and mitochondria
- Blocks ER stress pathways (UPR) implicated in cell death cascades following Ca2+ overload
- Mitochondrial membrane stabilization: taurine preserves membrane potential and reduces mPTP opening probability
- Multi-target: addresses calcium, oxidative stress, and ER dysfunction simultaneously
- Relevant downstream of NCX reversal: Ca2+ overload → mitochondrial damage cascade that taurine interrupts

Conclusion:: Taurine acts at multiple nodes downstream of Ca2+ overload to protect mitochondria and prevent cell death; mechanistically supports its use as a downstream AIMM cascade intervention Limitations:: Review only; primarily neuronal context; mechanistic extrapolation to ME/CFS skeletal muscle and cardiac contexts requires caution Certainty Assessment::

- *Quality:* Medium (peer-reviewed review, broad mechanistic coverage, no ME/CFS-specific data)
- *Replication:* Underlying mechanisms well-replicated in basic science literature
- *Score:* 0.55

23 Ahmadian et al. 2017 — Taurine RCT in Heart Failure: Anti-Inflammatory, Exercise Analog

Full Citation:: Ahmadian M, Roshan VD, Aslani E, Stannard SR. Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure. Ther Adv Cardiovasc Dis. 2017;11(7):185–194. DOI:: 10.1177/1753944717711138 PMID:: 28580833 Study Design:: Randomized controlled trial; 2-week intervention; before/after incremental exercise test Sample Size:: ~30 heart failure patients (taurine 1,500 mg/day vs placebo) Key Findings::

- CRP and platelet counts decreased significantly in taurine group post-supplementation
- Atherogenic indices (Castelli risk indices, atherogenic coefficient) improved with taurine but not placebo
- Benefits observed both at rest and in relation to incremental exercise
- No safety concerns with 2-week supplementation
- Exercise-intolerance population: relevant analog to ME/CFS post-exertional inflammation

Conclusion:: Short-term taurine supplementation reduces inflammation and atherogenic risk in heart failure patients with exercise intolerance; provides proof-of-concept that taurine has measurable clinical effects in a population sharing key features with ME/CFS (exercise intolerance, oxidative stress, cardiac dysfunction) Limitations:: Small n; 2-week duration only; heart failure patients not ME/CFS; no measures of mitochondrial function or calcium handling Certainty Assessment::

- *Quality:* Medium (RCT design, small n, short duration, analog population)
- *Replication:* One of few RCTs in exercise-intolerance population
- *Score:* 0.50

24 McGurk et al. 2022 — Systematic Review: Taurine in Heart Failure (Sobering)

Full Citation:: McGurk KA, Kasapi M, Ware JS. Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Res. 2022;7:9. DOI:: 10.12688/wellcomeopenres.17505.3 PMID:: 35855073 Study Design:: Systematic review and meta-analysis; PRISMA methodology Sample Size:: 11 studies included; dilated cardiomyopathy and heart failure populations Key Findings::

- Taurine doses ranged from 500 mg to 6 g/day across included studies
- No significant adverse effects reported across all studies
- Meta-analysis of ejection fraction and stroke volume: non-significant effect in all-cause heart failure
- Only 1 of 11 studies met high-quality methodological standards
- Formal well-powered RCTs needed before any clinical recommendation

Conclusion:: Despite strong theoretical rationale and preclinical support, taurine supplementation has not demonstrated robust clinical benefit in human heart failure; this is a critical null signal for the AIMM-taurine hypothesis — theoretical mechanism does not automatically translate to clinical outcomes Limitations:: Very few high-quality studies; heterogeneous populations and dosing; limited follow-up durations in underlying trials Certainty Assessment::

- *Quality:* Medium-high for systematic review quality; underlying studies low quality
- *Replication:* Sobering: null/non-significant meta-analytic signal despite mechanistic rationale
- *Score:* 0.55

25 Zhang et al. 2020 — Taurine Reverses Mitochondrial Ca2+ Overload via TRPC6/H2S (Analog)

Full Citation:: Zhang R, Wang X, Gao Q, et al. Taurine Supplementation Reverses Diabetes-Induced Podocytes Injury via Modulation of the CSE/TRPC6 Axis and Improvement of Mitochondrial Function. Nephron. 2020;144(2):84–95. DOI:: 10.1159/000503832 PMID:: 31865328 Study Design:: Animal and cell culture model (diabetic nephropathy); taurine supplementation intervention Sample Size:: Animal model (STZ-diabetic rats) + in vitro podocyte cultures Key Findings::

- Taurine supplementation reduced diabetes-induced Ca2+ overload in kidney podocytes
- Mechanism: taurine upregulates CSE (cystathionine gamma-lyase) → H2S production → TRPC6 channel downregulation → reduced Ca^2+^ influx
- Mitochondrial function improved: membrane potential restored, ROS reduced, apoptosis decreased
- Urinary protein excretion and cell death reduced
- Provides a detailed molecular mechanism: taurine → H2S → calcium channel suppression → mitochondrial protection

Conclusion:: Identifies a taurine → H2S → TRPC6 → calcium overload mitigation → mitochondrial protection pathway; mechanistically relevant to AIMM as evidence that taurine can interrupt calcium-driven mitochondrial damage in non-cardiac, non-neuronal tissue Limitations:: Animal/cell model only; diabetic context; TRPC6 not established as primary channel in ME/CFS; H2S pathway relevance to AIMM muscle context not validated Certainty Assessment::

- *Quality:* Low-medium (animal model, single group, no independent replication, indirect ME/CFS relevance)
- *Replication:* Mechanism consistent with broader taurine calcium-buffering literature
- *Score:* 0.45

References

Shahbaz, Shokrollah, Mohammed Osman, Hadeel Syed, Andrew Mason, Rhonda J Rosychuk, Jan Willem Cohen Tervaert, and Shokrollah Elahi. 2025. “Integrated Immune, Hormonal, and Transcriptomic Profiling Reveals Sex-Specific Dysregulation in Long COVID Patients with ME/CFS.” Cell Reports Medicine 6 (11): 102449. https://doi.org/10.1016/j.xcrm.2025.102449.